We scan new podcasts and send you the top 5 insights daily.
Although the POUT trial established adjuvant platinum chemotherapy for upper tract urothelial cancer, the carboplatin subgroup yielded a weaker overall survival hazard ratio of 0.86 with drifting disease-free survival. Because carboplatin historically failed in neoadjuvant bladder cancer, guidelines like ESMO restrict recommendations to cisplatin, leaving cisplatin-ineligible patients facing substantial toxicity—44% grade 3 or 4 adverse events in POUT—without convincing survival data.
An expert would not offer just the adjuvant portion of the EV-Pembro regimen to a patient who went straight to surgery, even though the full perioperative (neoadjuvant + adjuvant) regimen is approved. This highlights a strict adherence to trial data, where the lack of specific evidence for a purely adjuvant application prevents off-label use.
Despite broad approvals based on intent-to-treat populations, adjuvant immune checkpoint inhibitors have shown hazard ratios above 1.0 for both disease-free and overall survival in upper tract subsets across trials like CheckMate 274 (HR 1.23) and IMvigor010. Consequently, oncologists hesitate to extrapolate bladder cancer trial outcomes to upper tract disease, as dedicated evidence demonstrating a therapeutic benefit in this anatomical subgroup remains absent.
In muscle-invasive bladder cancer, cisplatin ineligibility is frequently due to renal insufficiency caused by large, aggressive tumors obstructing the ureter. This redefines this patient group as having more advanced local disease, rather than simply being unfit for chemotherapy, explaining their poor outcomes with surgery alone.
While cisplatin is standard in most urothelial cancer settings, carboplatin is an acceptable adjuvant option specifically after nephroureterectomy for upper tract disease. This is a logical adaptation, as patients have lost a kidney, increasing their risk of renal dysfunction with the more nephrotoxic cisplatin.
Even though CheckMate 274 showed improved disease-free survival in PD-L1-positive patients overall, oncologists caution against relying on PD-L1 to prescribe adjuvant nivolumab for upper tract tumors. Across urothelial cancer trials—including frontline metastatic settings—the PD-L1 biomarker has repeatedly failed to predict outcomes reliably. Furthermore, regulatory labels do not mandate PD-L1 testing, making it an unreliable surrogate for overcoming negative upper tract checkpoint inhibitor performance.
The practice-changing Keynote B15 trial showed strong efficacy for neoadjuvant EV-Pembro. However, about half of patients discontinued treatment due to side effects. This creates a clinical paradox: patients who complete the full regimen may be over-treated, while those who stop early due to toxicity may be under-treated, complicating patient management and counseling.
Despite the perception that cisplatin-ineligible patients have worse disease biology, the pathologic complete response rates to neoadjuvant EV Pembro were nearly identical (56-57%) in both cis-ineligible (KEYNOTE-905) and cis-eligible (KEYNOTE-B15) trials. This suggests the regimen's high efficacy may overcome underlying biological differences.
Some oncologists are stopping guideline-supported perioperative treatment regimens early if a patient achieves a pathologic complete response (pCR) from neoadjuvant therapy alone. This practice is considered premature and risky, as data from dedicated de-escalation trials like VOLGA is not yet available to support it.
The demonstrated superiority of the enfortumab vedotin (EV) and pembrolizumab combination over platinum chemotherapy has effectively made the Galski criteria, used for determining cisplatin eligibility, irrelevant. This marks a major paradigm shift in how frontline bladder cancer is approached, moving beyond platinum-based decisions.
The widely used TCHP chemotherapy regimen is weakening under scrutiny. Multiple randomized trials now show that adding carboplatin (the 'C') provides no additional benefit in shrinking tumors but increases toxicity, directly challenging its standing as a recommended standard of care in guidelines.